Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
According to health authorities guidances (FDA 2006, EMA(European Medicines Agency) 2009) for gene therapy clinical trials, observing subjects for delayed adverse events for 15 years is recommended. This purpose of this long-term follow-up study is to evaluate the safety and efficacy in patients who have ever received lentiviral-based gene-edited immune cells which are manufactured by Pell Bio-Med Technology Co. Ltd.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjent otrzymał wcześniej terapię zmodyfikowanymi genetycznie komórkami odpornościowymi wyprodukowanymi przez Pell Bio-Med Technology Co. Ltd. (samodzielnie lub łącznie z innymi lekami)
- •Ostatnie podanie terapii było w ciągu ostatnich 15 lat
- •Pacjent lub jego rodzic/opiekun może podpisać świadomą zgodę na uczestnictwo w badaniu
Simplified criteria — AI translation
Trial details
- Last updated (source)
- October 9, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (5)
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung, Taiwan
National Taiwan University Hospital
Taipei, Taiwan
Taipei Veterans General Hospital
Taipei, Taiwan
Chi Mei Medical Center
Tainan, Taiwan
Taipei Medical University - Taipei Medical University Hospital
Taipei, Taiwan
Trial contact
T. Hsun Lin, MSc
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/10/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.